TECHNOLOGY PLATFORMS
Therapeutic Technology & Platforms
Challenging the status quo, we are powering immunoscience with leading-edge technology to push the boundaries of discovery.
Do you believe each day holds boundless
Our Areas of R&D
Oncology
Since 2023, Genventis have collaborated with patient on a variety of solid tumors and blood cancer disorders such as lymphoma, leukemia, multiple myeloma, aplastic anemia and sickle cell anemia. We possess specialized expertise in hematopoietic stem cell transplantation (HSCT), cellular therapy and gene therapy.
Cardiovascular & Metabolic
We focus on developing innovative therapies that address the underlying causes of cardiovascular and metabolic diseases, aiming to improve long-term health outcomes and quality of life. Our work spans conditions such as heart failure, type 2 diabetes, and dyslipidemia, with the goal of delivering meaningful impact for patients and healthcare providers alike.
Neurology
Clients leverage a broad range of expertise in neurological and psychiatric disorders possessed by our neuroscience therapeutic research unit. We have significant experience in traumatic brain injury, stroke, epilepsy, autism, depression, schizophrenia and substance use disorders.
Vaccines and Infectious Diseases
As a biotech company, Geventis has worked on nearly every epidemic and pandemic since our founding in 2023, including HIV-AIDs, Zika Virus, Ebola, SARS, MERS, H1N1, and COVID-19.
Immunology
Patients seek Genventis’s respiratory and immunology clinical research services for a variety of disorders including age-related rheumatoid arthritis, COPD, SLE and autoimmune disease.
Rare Disease
We are committed to discovering and developing treatments for rare and underserved conditions, bringing hope where options are limited. Our work focuses on conditions such as Pompe disease, Gaucher disease, and Duchenne muscular dystrophy, aiming to transform lives through innovative and targeted therapies.
R&D Technologies
With capabilities in multiple drug modalities, including small molecules, protein therapeutics, antisense oligonucleotides and gene therapy, Genventis pursues the most appropriate modality for each target.
Small Molecules
Small molecule therapeutics are often taken orally as a pill and can readily distribute into cells and tissues, which differentiates them from other modalities. Medicinal chemists aim to optimize the potency of starting molecules toward the desired biological target along with physical properties to maximize the potential of the medicine to treat disease.
.jpg)
Protein Therapeutics
Therapeutic proteins, also referred to as biologics, are often as much as a thousand times the size of small-molecule drugs. Although this type of drug is much more complicated to make and characterize, using biologics allows scientists to attack serious disease in ways that might not be possible with other technologies.
Antisense Oligonucleotides
Antisense oligonucleotides (ASOs) are synthetic, single-stranded nucleic acids consisting of eight to 50 nucleotides which bind to RNA and are designed to interfere with target gene expression. ASOs utilize several distinct mechanisms to alter RNA and either restore desired protein expression or reduce and modify toxic proteins.
.jpg)
Cell Therapy
Autologous cell therapies have demonstrated strong clinical benefit, but their complex and individualized manufacturing limits broad accessibility. Early efforts in allogeneic therapies have faced challenges, particularly with cell persistence and durability.
Antibody Drug Conjugates
At Genventis, we are developing next-generation antibody-drug conjugates (ADCs)—targeted therapies that deliver potent anti-cancer drugs directly to tumor cells. By combining a tumor-targeting antibody with a cytotoxic payload, ADCs are designed to maximize cancer cell killing while minimizing harm to healthy tissues.
.jpg)
Monoclonal Antibodies
Monoclonal antibodies (mAbs) are specially designed proteins that recognize and attach to specific cellular targets. Once attached, they can either help the immune system destroy the cancer or block signals that the cancer cells need to grow and survive.
Partner With Us
We welcome the opportunity to explore working with other innovators. If your company or institution would like to share a potential asset or platform technology for collaboration, contact us today.
